20 articles
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
New study finds 27% of patients with treatment-resistant hypertension have elevated cortisol levels that could explain medication failures.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
